<DOC>
	<DOCNO>NCT00520936</DOCNO>
	<brief_summary>To determine response rate pemetrexed give every 21 day treatment child relapse refractory osteosarcoma , Ewing 's sarcoma/peripheral primitive neuroectodermal tumor ( PNET ) , rhabdomyosarcoma , neuroblastoma , ependymoma , medulloblastoma/supratentorial PNET non-brain stem high-grade glioma .</brief_summary>
	<brief_title>A Study Pemetrexed Children With Recurrent Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients must osteosarcoma , Ewing 's sarcoma , medulloblastoma , neuroblastoma , rhabdomyosarcoma , ependymoma highgrade nonbrainstem glioma Measurable disease Eastern Cooperative Oncology Group ( ECOG ) performance 0,1,2 Adequate renal , liver bone marrow function Patient 's current disease state must one know curative therapy therapy proven prolong survival acceptable quality life Growth factor support platelet white cell number function must administer within last 7 day prior enrollment ( 14 day Neulasta ) Patients central nervous system ( CNS ) tumor stable decrease dose dexamethasone corticosteroid 7 day prior enrollment Patients uncontrolled infection Patients receive pemetrexed previously Patients pleural effusion ascites</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>